Lung diseases are associated with higher mortality on patients undergoing on Tanscatheter aortic-valve implantation (TAVI). Impact of lung diseases are poorly investigated on alternative access.

His study aim to compare 30-day and 1-year mortality after transaortic (TA) or transfemoral (TF) TAVI on patients with chronic lung diseases.

All patients with symptomatic aortic stenosis were consecutively included between January 2012 and January 2016. Spirometry was performed and interpreted by a pneumologyst. Pulmonary diseases were defined according based on spirometric results. The allocation strategy for SAVR or TAVI, the way, the valve selection, was at the discretion of our local multidisciplinary Heart Team. Clinical follow-up was performed by clinical visit or phone consultation. The primary end point was the death from any cause after TAVI.

A total of 164patients were analysed. Comparing 82 TA to 82 TF patients mortality was similar at 30 day (RR=1.24 (0.52–2.92) P=0.692). Mortality rates after 1year was also similar (RR=1.35 (0.76–2.42), P=0.308). There was no impact in lenght of hospitalisation (TF: n=7.2±2 days, TA n=8±3.3 days P=0.108) (Fig. 1).

In patients undergoing on TAVI, these results suggest that compared with the TF in TA approach lung diseases do not impact mortality. Access selection should not be impact by a lung dieases.